Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 June 2016
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA694)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 April 2021
Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)Product type:GuidanceProgramme:NICE guidelinePublished: 14 December 2023
Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over (TA1002)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 September 2024
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 June 2016
Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 February 2016
Familial hypercholesterolaemia: identification and management (CG71)Product type:GuidanceProgramme:Clinical guidelineLast updated: 4 October 2019Published: 27 August 2008
Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 July 2022
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 October 2021
Metreleptin for treating lipodystrophy (HST14)Product type:GuidanceProgramme:Highly specialised technologies guidancePublished: 24 February 2021
Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal) (TA961)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 March 2024
Sebelipase alfa for treating Wolman disease (HST30)Product type:GuidanceProgramme:Highly specialised technologies guidancePublished: 10 January 2024